Compare PSNY & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNY | STOK |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | PSNY | STOK |
|---|---|---|
| Price | $12.59 | $32.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $33.11 |
| AVG Volume (30 Days) | 322.2K | ★ 938.4K |
| Earning Date | 09-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $2,547,619,000.00 | $205,632,000.00 |
| Revenue This Year | $49.69 | $430.24 |
| Revenue Next Year | $44.50 | N/A |
| P/E Ratio | ★ N/A | $46.63 |
| Revenue Growth | 24.82 | ★ 1128.17 |
| 52 Week Low | $11.75 | $5.35 |
| 52 Week High | $42.60 | $38.69 |
| Indicator | PSNY | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 54.65 |
| Support Level | $11.75 | $31.50 |
| Resistance Level | $14.87 | $34.05 |
| Average True Range (ATR) | 1.31 | 2.24 |
| MACD | 0.63 | -0.04 |
| Stochastic Oscillator | 66.41 | 50.15 |
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.